Survodutide
About
About Survodutide
Survodutide is a GLP-1/glucagon dual agonist developed by Boehringer Ingelheim and Zealand Pharma, in Phase III trials for obesity and non-alcoholic steatohepatitis (NASH). It has shown 18–19% weight loss in Phase II with particularly strong effects on liver fat reduction, making it a leading candidate for MASH/NASH treatment beyond weight loss. The glucagon component drives hepatic fat clearance while GLP-1 handles appetite and glycemic control.
Science
Mechanism of Action
Dual agonism at GLP-1 and glucagon receptors increases hepatic fat oxidation and lipolysis via glucagon signaling while GLP-1 receptor activation suppresses appetite and enhances insulin secretion in a glucose-dependent manner.
Dosing
Typical Protocol
0.6–4.8 mg subcutaneous injection once weekly; titrated over 16 weeks in Phase III protocols.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Regulatory
Legal Status in 2026
This compound occupies a regulatory grey area in 2026. It is neither explicitly FDA-approved nor clearly illegal for personal use, but it lacks formal clinical approval and may not be legally sold for human use in all contexts. Proceed with caution: source quality is variable, and regulatory status can change. Always consult a physician.
Evidence
Evidence Tier
Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard — effects have been measured in controlled conditions and results are peer-reviewed and reproducible.
Find a Verified Provider
See which Vial-verified providers offer Survodutide — with trust scores, legal credentials, and pricing transparency.